Coinfection

Pharmasset Starts Phase 3 Trials of PSI-7977 Without Interferon

Pharmasset, Inc. announced this week that it has begun a Phase 3 program of studies of its hepatitis C virus (HCV) polymerase inhibitor PSI-7977 taken once-daily in combination with ribavirin but not pegylated interferon. These trials will enroll previously untreated people with HCV genotype 2 or 3, and patients with any genotype who cannot use interferon.alt

Read more:

EACS 2011: Predictors of HCV Viral Load in HIV/HCV Coinfected Patients

Hepatitis C virus (HCV) RNA levels rise over time in HIV/HCV coinfected people, reducing the chances of sustained response to interferon-based treatment. But antiretroviral therapy may help control HCV viral load and contribute to higher likelihood of treatment success, according to a report presented at the 13th European AIDS Conference (EACS 2011) this month in Belgrade.alt

Read more:

ICAAC 2011: Maraviroc May Reduce Liver Fibrosis in HIV/HCV Coinfected People

Adding the CCR5 blocker maraviroc (Selzentry) to an antiretroviral regimen reduced liver stiffness, an indicator of fibrosis, according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.

Read more:

IDSA 2011: Boceprevir Increases Hepatitis C Treatment Response for HIV/HCV Coinfected People

The recently approved hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis) added to pegylated interferon/ribavirin significantly improved the likelihood of virological response at week 24 in HIV/HCV coinfected patients, according to a late-breaker presentation at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA 2011) in Boston.alt

Read more:

ICAAC 2011: Didanosine, Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV Coinfected People

Use of didanosine (ddI, Videx) -- along with higher hepatitis C virus (HCV) RNA level, male sex, and older age -- was a significant risk factor for liver fibrosis in people with HIV/HCV coinfection, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.alt

Read more:

EACS 2011: Antiretroviral Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected People

Earlier initiation of antiretroviral therapy (ART) and spending more time on HIV treatment may help slow liver disease progression in HIV/HCV coinfected patients, according to an Italian study using non-invasive methods presented at the 13th European AIDS Conference (EACS 2011) last week in Belgrade.alt

Read more:

Hepatitis B and C Coinfection among HIV Positive People in the U.S.

Liver disease and coinfection with hepatitis B or C are common among people with HIV, according to a recent analysis, leading researchers to recommend that viral hepatitis screening, vaccination, and treatment should be considered a priority for HIV positive individuals.alt

Read more:

ICAAC 2011: Interferon May Reduce Liver Disease Progression in HIV/HCV Coinfected Relapsers

Unsuccessful interferon-based therapy for chronic hepatitis C virus (HCV) infection appeared to improve or slow liver fibrosis progression in HIV/HCV coinfected people, but this was usually temporary, according to 2 studies presented the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.

Read more:

Alarming Rate of Hepatitis C Re-infection among HIV+ Gay Men

One-third of HIV positive men who have sex with men (MSM) who were treated for acute hepatitis C virus (HCV) infection in Amsterdam became re-infected within 2 years, indicating a need for improved prevention efforts, according to a recent report.alt

Read more: